Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer
Name:
35393425.pdf
Size:
559.8Kb
Format:
PDF
Description:
Identified with Open Access button
Authors
Telli, M. L.Tolaney, S. M.
Shapiro, G. I.
Middleton, M.
Lord, S. R.
Arkenau, H. T.
Tutt, A.
Abramson, V.
Dean, Emma J
Haddad, T. C.
Wesolowski, R.
Ferrer-Playan, J.
Goddemeier, T.
Grombacher, T.
Dong, J.
Fleuranceau-Morel, P.
Diaz-Padilla, I.
Plummer, R.
Affiliation
Stanford University School of Medicine, Stanford, CA, USAIssue Date
2022
Metadata
Show full item recordAbstract
Platinum derivatives are commonly used for the treatment of patients with metastatic triple-negative breast cancer (TNBC). However, resistance often develops, leading to treatment failure. This expansion cohort (part C2) of the previously reported phase 1b trial (NCT02157792) is based on the recommended phase 2 dose of the combination of the ataxia-telangiectasia and Rad3-related (ATR) inhibitor berzosertib and cisplatin observed in patients with advanced solid tumors, including TNBC. Forty-seven patients aged ≥18 years with advanced TNBC received cisplatin (75 mg/m2; day 1) and berzosertib (140 mg/m2; days 2 and 9), in 21-day cycles. Berzosertib was well tolerated, with a similar toxicity profile to that reported previously for this combination. The overall response rate (90% confidence interval) was 23.4% (13.7, 35.8). No relevant associations were observed between response and gene alterations. Further studies combining ATR inhibitors with platinum compounds may be warranted in highly selected patient populations.Citation
Telli ML, Tolaney SM, Shapiro GI, Middleton M, Lord SR, Arkenau HT, et al. Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer. Vol. 8, npj Breast Cancer. Springer Science and Business Media LLC; 2022.Journal
NPJ Breast CancerDOI
10.1038/s41523-022-00406-0PubMed ID
35393425Additional Links
https://dx.doi.org/10.1038/s41523-022-00406-0Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1038/s41523-022-00406-0
Scopus Count
Collections
Related articles
- Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours.
- Authors: Shapiro GI, Wesolowski R, Devoe C, Lord S, Pollard J, Hendriks BS, Falk M, Diaz-Padilla I, Plummer R, Yap TA
- Issue date: 2021 Aug
- Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types.
- Authors: Terranova N, Jansen M, Falk M, Hendriks BS
- Issue date: 2021 Feb
- CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method.
- Authors: Javed SR, Lord S, El Badri S, Harman R, Holmes J, Kamzi F, Maughan T, McIntosh D, Mukherjee S, Ooms A, Radhakrishna G, Shaw P, Hawkins MA
- Issue date: 2024 Feb
- Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer.
- Authors: Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul S, Moore JA, Yilmaz B, Ogbonna D, Karp DD, Dumbrava E, Tsimberidou AM, Hong DS, Rodon Ahnert J, Milton DR, Zheng X, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F
- Issue date: 2023 Jul 15
- Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.
- Authors: Konstantinopoulos PA, Cheng SC, Wahner Hendrickson AE, Penson RT, Schumer ST, Doyle LA, Lee EK, Kohn EC, Duska LR, Crispens MA, Olawaiye AB, Winer IS, Barroilhet LM, Fu S, McHale MT, Schilder RJ, Färkkilä A, Chowdhury D, Curtis J, Quinn RS, Bowes B, D'Andrea AD, Shapiro GI, Matulonis UA
- Issue date: 2020 Jul